Translating unique human immune responses
into superior medicines
Memo Therapeutics AG is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with viral infections and cancer.
Our lead program, potravitug, currently in Phase II development, is the most potent antibody ever tested in clinical trials to treat BK viremia in kidney transplant recipients. BK viremia can lead to nephropathy, loss of kidney function, as well as organ failure and rejection.
Other programs consist of therapeutic antibodies focusing on novel oncology targets both alone and in partnership.
About us
Find out more about us and our mission to change the standard of care for patients with viral infections and cancer.
BKV
Our most advanced program, potravitug, focuses on BK polyomavirus infection which can seriously affect kidney transplant recipients. Find out more about how we hope to offer a solution for patients who currently have no effective treatment alternative available to them.
Oncology
We are mining antibody repertoires of tumor infiltrating B-cells from elite cancer patients to discover superior antibodies and targets to develop new medicines.
DROPZYLLA
Phase 2 for potravitug targeting BKV
We have completed recruiting patients in the largest placebo controlled clinical trial for treatment of BK viremia in kidney transplant recipients ever conducted. SAFE KIDNEY II (NCT05769582) is a Phase II double-blind, randomized, placebo-controlled trial with 90 patients in the USA. The trial aims to determine the safety, tolerability and efficacy of potravitug.
Latest news
Latest publications
Upcoming events
